Insmed moves closer to $6B opportunity as PAH drug shows long-term durability
Insmed's PAH drug shows long-term durability data supporting a $6B market opportunity.
Insmed Incorporated
Commercial-stage biopharmaceutical company developing therapies for rare and serious diseases, including ARIKAYCE for refractory NTM lung infection and brensocatib for bronchiectasis.
Company Info
Upcoming Milestones & Key Dates
Late 2026
PDUFA
Brensocatib FDA decision (bronchiectasis)
2027 H1
Clinical Readout
TPIP Phase 3 long-term data
Clinical Development Pipeline
ARIKAYCE (amikacin liposome inhalation suspension)
Target: AmikacinBrensocatib
Target: DPP1Treprostinil palmitil (TPIP)
Target: ProstacyclinRecent News
Leadership Team
Will Lewis
Chair and Chief Executive Officer
Sara Bonstein
Chief Financial Officer
Chief Medical Officer
Head of Clinical Development
Careers & Job Openings